Panbela Announces Clinical Trial With Moffitt Cancer Center For Phase I/II Program In STK11 Mutant Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Panbela announced a clinical trial in collaboration with Moffitt Cancer Center for a Phase I/II program targeting STK11 mutant non-small cell lung cancer. The trial aims to evaluate the safety and efficacy of Panbela's drug candidate.
May 22, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Panbela's collaboration with Moffitt Cancer Center for a Phase I/II clinical trial in STK11 mutant non-small cell lung cancer may positively impact its stock price.
The announcement of a clinical trial collaboration with Moffitt Cancer Center for a Phase I/II program in STK11 mutant non-small cell lung cancer is a significant development for Panbela. This partnership may lead to positive results in the trial, which could increase the value of Panbela's drug candidate and potentially boost its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100